Guessing this will be added to the SNY conflicts discussions

[joeypotsandpans]

Talk about a company that doesn't want to leave any stone unturned...first link is today's news, second link will give a better picture of the study comparisons and side effects. Once a day injection for T2's GLP-1 combination with Lantus compared favorably to Metformin. Right in Novo's backyard so to speak as this partner is situated right in Copenhagen...SNY is aggressively looking to remain the absolute leader in the treatment of Diabetes IMO and doesn't look to be taking any prisoners...this is another continued use of Lantus, they're looking out on all their fronts/products in maintaining and growing market share in the space and being the one stop shop (Basal, Prandial, GLP's, you name it) when it comes to tackling Diabetes....again if I'm a Novo rep (or investor for that matter), I'd be looking to jump ship

money.cnn.com/news/newsfeeds/articles/globenewswire/10143619.htm


www.nice.org.uk/advice/esnm26/chapter/key-points-from-the-evidence

[mssciguy]

Will be nice to see these kinds of discussions and studies resulting from Afrezza.
They can't ignore the success stories on social media.

[mnholdem]

Don't forget the GLP-1 that Sanofi has secured the rights to AND for which recently Sanofi applied for the patent in (March 2015).

Class name: Blood sugar affecting diabetes glucagon, glucagon-like peptide (e.g., glp-1, etc.) or derivative affecting or utilizing
Publication date: 2015-03-19
Patent application number: 20150080298

Excerpt (re: Example 4):

Administration of GLP-1 in an Inhalable Dry Powder to Type 2 Diabetic Patients

[0175] A Phase 1 clinical trial of GLP-1/FDKP inhalation powder was conducted in patients suffering with Type 2 diabetes mellitus to assess the glucose levels of the patients before and after treatment with GLP-1 dry powder formulation by pulmonary inhalation. These studies were conducted according to Example 1 and as described herein. GLP-1 inhalation powder was prepared as described in U.S. patent application Ser. No. 11/735,957, which disclosure is incorporated herein by reference. The dry inhalation powder contained 1.5 mg of human GLP-1(7-36) amide in a total of 10 mg dry powder formulation containing FDKP in single dose cartridge. For this study, 20 patients with Type 2 diabetes, including adult males and postmenopausal females, were fasted overnight and remained fasted for a period of 4 hr after GLP-1 inhalation powder administration. The dry powder formulation was administered using the MEDTONE® dry powder inhaler (MannKind Corporation), and described in U.S. patent application Ser. No. 10/655,153, which disclosure is incorporated herein by reference in its entirety.

[0176] Blood samples for assessing serum glucose levels from the treated patients were obtained at 30 min prior to dosing, at dosing (time 0), and at approximately 2, 4, 9, 15, 30, 45, 60, 90, 120 and 240 min following GLP-1 administration. The serum glucose levels were analyzed for each sample.

[0177] FIG. 11 is a graph showing the results of these studies and depicts the glucose values obtained from six fasted patients with Type 2 diabetes following administration of a single dose of an inhalable dry powder formulation containing GLP-1 at various time points. The glucose values for all six patients decreased following administration of GLP-1 and remained depressed for at least 4 hrs after administration at the termination of the study.

[0178] FIG. 12 is a graph showing the mean glucose values for the group of six fasted patients with Type 2 diabetes whose glucose values are shown in FIG. 11. In FIG. 12, the glucose values are expressed as the mean change of glucose levels from zero time (dosing) for all six patients. FIG. 12 shows a mean glucose drop of approximately 1 mmol/L, which is approximately equivalent to from about 18 mg/dL to about 20 mg/dL, is attained by the 30 min time point. This mean drop in glucose levels to last for 120 min. The changes are larger in subjects with higher baseline glucose and more prolonged, whereas in 2 of the 6 subjects, those subjects with the lowest baseline fasted blood glucose, showed only a transient lowering of glucose levels in this timeframe (data not shown). It was noted that those with higher fasting glucose do not typically have the same insulin response as those with lower values, so that when stimulated, those subjects with higher fasting glucose typically exhibit a greater response than those whose glucose value are closer to normal.


Read more: www.faqs.org/patents/app/20150080298#ixzz3hHZ7qjOi

MnHoldem's NOTE: Of interest to me was the use of the MEDTONE® dry powder inhaler (MannKind Corporation), which indicates to me that Sanofi has been working for some time with MannKind, well before the partnership agreement.